FluMist (Seasonal Influenza Vaccines) Forecast and Market Analysis

Date: November 30, 2012
Pages: 36
Price:
US$ 3,495.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: F56EA361A60EN
Leaflet:

Download PDF Leaflet

FluMist (Seasonal Influenza Vaccines) Forecast and Market Analysis
FluMist (Seasonal Influenza Vaccines) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “FluMist (Seasonal Influenza Vaccines) Forecast and Market Analysis”. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

FluMist is a live, attenuated vaccine designed to immunize recipients against influenza. The viruses incorporated into FluMist are propagated in specific pathogen-free eggs, isolated by filtration and centrifugation, and sterilized via filtration. FluMist is the only intranasal influenza vaccine currently available in the US and Europe, where it is marketed by MedImmune, a subsidiary of AstraZeneca.

Scope
  • Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on FluMist including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for FluMist for the top six countries from 2012 to 2022.
  • Sales information covered for the US, Germany, the UK, Italy, Spain and China.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of FluMist performance
  • Obtain sales forecast for FluMist from 2012 to 2022 in the US, Germany, the UK, Italy, Spain and China.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Catalyst
2.2 Related Reports

3 DISEASE OVERVIEW

3.1 Etiology and Pathophysiology
  3.1.1 Etiology
  3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis

4 DISEASE MANAGEMENT

4.1 Influenza Vaccination Policy

5 COMPETITIVE ASSESSMENT

5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profile - FluMist
  5.3.1 Overview
  5.3.2 Efficacy
  5.3.3 Safety
  5.3.4 SWOT Analysis
  5.3.5 Forecast

6 APPENDIX

6.1 Bibliography
6.2 Abbreviations
6.3 Methodology
6.4 Forecasting Methodology
  6.4.1 Vaccine Coverage
  6.4.2 Influenza Vaccine Tender System Assumptions
  6.4.3 General Pricing Assumptions
  6.4.4 Individual Vaccine Assumptions
6.5 Physicians and Specialists Included in this Study
6.6 Primary Research - Prescriber Survey
6.7 About the Authors
  6.7.1 Authors
  6.7.2 Global Head of Healthcare
6.8 About GlobalData
6.9 Contact Us
6.10 Disclaimer

LIST OF TABLES

Table 1: Notable Influenza Pandemics
Table 2: Symptoms of Influenza
Table 3: Influenza Vaccination Recommendation Committees by Country
Table 4: Most Administered Influenza Vaccines by Country in the Global Markets, 2012
Table 5: Leading Influenza Vaccines, 2012
Table 6: Product Profile - FluMist
Table 7: FluMist SWOT Analysis, 2012
Table 8: Global Sales Forecasts ($m) for FluMist, 2012-2022
Table 9: Epidemiology and Market Forecast Chinese Influenza Vaccination Rates (%), 2012-2022
Table 10: Physicians Surveyed, By Country

LIST OF FIGURES

Figure 1: Influenza Virus Structure

Ask Your Question

FluMist (Seasonal Influenza Vaccines) Forecast and Market Analysis
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: